RiboMed files new patent application: Methods and Reagents for Detecting CpG Methylation with a Methyl CpG Binding Protein (MBP)

Inventors:            Michelle M. Hanna and David McCarthy


ABSTRACT

The present invention provides a simple and sensitive technology for the detection of CpG methylation in DNA without chemical modification of sample DNA by bisulfite treatment or PCR amplification. Signal generation is based on an Abscription (Abortive Transcription) technology in which DNA signal generators called Abortive Promoter Cassettes (APCs) are bound to target mCpG sites via mCpG target specific probes based on methyl binding polypeptides or methyl binding domains thereof. RNA polymerase produces uniform, short RNA molecules from synthetic promoters in APCs as signals of the presence of methylated CpGs. Detection of CpG methylation and  hypermethylation of DNA targets such as CpG islands provides a convenient means for detecting and monitoring cancer in a subject.


Advertisements

One response to “RiboMed files new patent application: Methods and Reagents for Detecting CpG Methylation with a Methyl CpG Binding Protein (MBP)

  1. Pingback: RiboMed has a new Home and you are invited! « Ribomed Biotechnologies, Inc.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s